Signaling pathways
-
BA8176 LodenafilSummary: Potent phosphodiesterase type 5 inhibitor. - BA8177 PF-06445974Summary: PF-06445974 is a positron emission tomography (PET) compound effective at, <1nM.
- BA8178 GSK356278Summary: GSK356278 is a potent, selective, orally active and blood-brain barrier-crossing phosphodiesterase 4 inhibitor with values of 8.6, 8.8 and 8.7 for human PDE4A, PDE4B and PDE4D, respectively.
- BA8179 Enpp-1-IN-2Summary: Enpp-1-IN-2 is a potent (ectonucleotide pyrophosphatase/phosphodiesterase 1) inhibitor with values of 0.26, 0.48, and 2.0 μM as determined by TG-mAMP, pNP-TMP, and ATP methods, respectively.
- BA8180 TAK-915Summary: TAK-915 is a potent, selective, blood-brain barrier-crossing and orally active inhibitor.
- BA8181 PDE12-IN-3Summary: PDE12-IN-3 is a phosphodiesterase 12 inhibitor with a pXC of 7.68.
- BA8182 DSR-141562Summary: DSR-141562 is a novel, orally active phosphodiesterase inhibitor that crosses the blood-brain barrier.
- BA8183 Autotaxin-IN-3Summary: Autotaxin-IN-3 is an inhibitor.
- BA8184 DovramilastSummary: Dovramilast (CC-11050) is a phosphodiesterase 4 inhibitor with oral activity that reduces the inflammatory response and improves mediated lung bacterial clearance.
- BA8185 CarbazeranSummary: Carbazeran is a potent phosphodiesterase inhibitor and is an aldehyde oxidase substrate.